Ligand Pharmaceuticals Incorporated (LGND) - Total Assets
Based on the latest financial reports, Ligand Pharmaceuticals Incorporated (LGND) holds total assets worth $2.19 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Ligand Pharmaceuticals Incorporated - Total Assets Trend (1994–2025)
This chart illustrates how Ligand Pharmaceuticals Incorporated's total assets have evolved over time, based on quarterly financial data. Also see LGND market cap overview for the company's overall valuation and market capitalisation.
Ligand Pharmaceuticals Incorporated - Asset Composition Analysis
Current Asset Composition (December 2025)
Ligand Pharmaceuticals Incorporated's total assets of $2.19 Billion consist of 53.3% current assets and 46.7% non-current assets. Review LGND total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.2% |
| Accounts Receivable | $61.05 Million | 3.9% |
| Inventory | $9.13 Million | 0.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $422.31 Million | 27.1% |
| Goodwill | $101.54 Million | 6.5% |
Asset Composition Trend (1994–2025)
This chart illustrates how Ligand Pharmaceuticals Incorporated's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Ligand Pharmaceuticals Incorporated (LGND) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ligand Pharmaceuticals Incorporated's current assets represent 53.3% of total assets in 2025, a decrease from 89.1% in 1994.
- Cash Position: Cash and equivalents constituted 11.2% of total assets in 2025, down from 16.3% in 1994.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 33.0% of total assets, an increase from 0.0% in 1994.
- Asset Diversification: The largest asset category is intangible assets at 27.1% of total assets.
Ligand Pharmaceuticals Incorporated Competitors by Total Assets
Key competitors of Ligand Pharmaceuticals Incorporated based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Ligand Pharmaceuticals Incorporated - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 30.49 | 5.45 | 11.90 |
| Quick Ratio | 30.49 | 5.25 | 11.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.38 Billion | $288.21 Million | $395.79 Million |
Ligand Pharmaceuticals Incorporated - Advanced Valuation Insights
This section examines the relationship between Ligand Pharmaceuticals Incorporated's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.58 |
| Latest Market Cap to Assets Ratio | 3.90 |
| Asset Growth Rate (YoY) | 65.7% |
| Total Assets | $1.56 Billion |
| Market Capitalization | $6.09 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Ligand Pharmaceuticals Incorporated's assets at a significant premium (3.90x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Ligand Pharmaceuticals Incorporated's assets grew by 65.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Ligand Pharmaceuticals Incorporated (1994–2025)
The table below shows the annual total assets of Ligand Pharmaceuticals Incorporated from 1994 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.56 Billion | +65.71% |
| 2024-12-31 | $941.77 Million | +19.63% |
| 2023-12-31 | $787.22 Million | +3.22% |
| 2022-12-31 | $762.67 Million | -41.22% |
| 2021-12-31 | $1.30 Billion | -4.75% |
| 2020-12-31 | $1.36 Billion | -8.87% |
| 2019-12-31 | $1.49 Billion | +18.57% |
| 2018-12-31 | $1.26 Billion | +87.89% |
| 2017-12-31 | $671.02 Million | +11.54% |
| 2016-12-31 | $601.59 Million | +12.67% |
| 2015-12-31 | $533.93 Million | +106.93% |
| 2014-12-31 | $258.03 Million | +146.42% |
| 2013-12-31 | $104.71 Million | +0.43% |
| 2012-12-31 | $104.26 Million | -14.79% |
| 2011-12-31 | $122.35 Million | +61.93% |
| 2010-12-31 | $75.56 Million | -33.54% |
| 2009-12-31 | $113.70 Million | -33.68% |
| 2008-12-31 | $171.45 Million | -1.06% |
| 2007-12-31 | $173.28 Million | -46.86% |
| 2006-12-31 | $326.05 Million | +3.63% |
| 2005-12-31 | $314.62 Million | -5.37% |
| 2004-12-31 | $332.47 Million | +10.36% |
| 2003-12-31 | $301.25 Million | +11.32% |
| 2002-12-31 | $270.61 Million | +130.36% |
| 2001-12-31 | $117.47 Million | +3.57% |
| 2000-12-31 | $113.42 Million | -15.73% |
| 1999-12-31 | $134.60 Million | -13.72% |
| 1998-12-31 | $156.00 Million | +45.25% |
| 1997-12-31 | $107.40 Million | +5.19% |
| 1996-12-31 | $102.10 Million | +9.08% |
| 1995-12-31 | $93.60 Million | +100.43% |
| 1994-12-31 | $46.70 Million | -- |
About Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help figh… Read more